Top Banner
Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006 Copenhagen
20

Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Mar 27, 2015

Download

Documents

Alyssa Carney
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Quantification from a TB Perspective

Technical Briefing Seminar for Consultants on Procurement & Supply Management for

HIV, TB and MalariaJan. 31 2006 Copenhagen

Page 2: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Framework: Pharmaceutical Management Cycle

Selection

ProcurementManagementSupport

Distribution

Use

Policy and Legal Framework

Quantification

Page 3: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Quantifying Medicines and Supplies Needs

Purpose To estimate the quantity of medicines needed to ensure an uninterrupted supply and to fully cover estimated TB treatment requirements

Page 4: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Applications of Quantification (1)

• Prepare and justify a drug budget (e.g. for GFATM)

• Plan for new and expanding tuberculosis programs—e.g. DOTS expansion to other districts

• Optimize medicine budgets based on TB cases to be treated and the most cost-effective treatment approaches

QUAN 3

Page 5: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Applications of Quantification (2)

• Calculate emergency needs for disaster relief and epidemics

• Replenish an existing supply network that has become depleted of products

• Compare current consumption of medicines with tuberculosis treatment priorities and usage in other health systems

QUAN 4

Page 6: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Critical Issues in Quantification (1)

QUAN 7

1. Developing the medicine list (selection)

2. Preparing an action plan for quantification

3. Using centralized or decentralized quantification

4. Using manual or computerized methods for quantification

5. Estimating time requirements, including procurement period, stock-outs, safety stock

6. Filling the supply pipeline

Page 7: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Critical Issues in Quantification (2)

QUAN 8

7. Considering the impact of lead time at all levels (buffer stock: 6 months national; 3 months district)

8. Adjusting for program growth and for losses due to waste and theft

9. Cross-checking estimates produced with previous years of alternative methods

10.Estimating total procurement cost

11. Adjusting and reconciling final quantities in accordance with available funds

Page 8: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Quantification is difficult

• Must know accurate number of patients at all levels

• Must know number of patients in each category of treatment

• Must accurately calculate the quantity of each medicine and supplies needed to avoid under or over stock

Page 9: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Options for Quantification

1. Morbidity based: this is the WHO-recommended method that bases estimates on number of cases

2. Consumption based: An alternative method available to systems with a functioning DMIS to base estimate on past consumption—also useful for ordering or replacing stocks

3. Adjusted-consumption based: Estimates based on data from another region or health service

QUAN 5

Page 10: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Comparison of Quantification Methods

QUAN8

Consumption versus Morbidity

• Consumption – need good inventory records

• Morbidity- need patient attendance data

• Both methods – need data on existing stocks, lead times, costs

Page 11: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Morbidity Method (1)

1. Estimate number of expected cases per disease category in the projected year – e.g. 1000 cases category I for 12 months

2. Identify the number of tablets of each medicine selected to treat category I TB patient– 504 of isoniazid/rifampicin (RH)– 168 of pyrazinamide (Z)– 168 of ethambutol (E)

Page 12: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Morbidity Method (2)

3. Account for new cases during stock-out periods, safety stock, procurement period, and lead time

– 8 months total or 1000 category I cases

4. Multiply the number of tablets required by the total estimated cases

– 1000 category I cases x 504 units isoniazid/rifampicin = 504,000

– 1000 category I cases x 168 units pyrazinamide = 168,000

– 1000 category I cases x 168 units ethambutol = 168,000

Then add to these totals the number of tablets equal to an 8-month supply (504,000 x 1.67—8/12)

5. Subtract stock on hand and the result is amount to procure

Page 13: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Example of spreadsheet – Morbidity Method (1)

*Adjusted order factor in years: equals lead time plus safety stock (e.g., 6 months + 2 month = 8months = 0.67 years)

 

Treatment

Category

(A) Estimated Cases for

Year

(B) (C) (D) (E) (F)

Basic Units per Case (e.g.,

tab, vial)

Total Basic Units per

Product Needed

Adjusted Order

Factor *Quantity in

Stock

Total Quantity to

Procure

  (A x B) (0.67 x C)    

RH 150/75 mg tabs Cat. I 1000 504 504,000 337,680 52,000 789,680

Z 400 mg tabs Cat. I 1000 168 168,000 112,560 15,000 265,560

E 400 mg tabs Cat. I 1000 168 168,000 112,560 9,800 270,760

Page 14: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Example of spreadsheet – Morbidity Method (2)

 

Treatment Category

(G) Units per container (blister)

(H) (I) (J)

Number contain ers (blister) to

buy Container (blister)

Price Total Price US$

(F/G)   (G x H)

RH 150/75 mg tabs Cat. I 28 28,203 0.70 19,742

Z 400 mg tabs Cat. I 28 9,484 0.37 3,509

E 400 mg tabs Cat. I 28 9,670 0.57 5,512

Page 15: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Consumption Method (1)

1. Divide total annual consumption of specific medicine units by 12 to get average monthly consumption

– Isoniazid/Rifampicin = 259,200 ÷ 12 = 21,600 units/month

2. Account for amount of units required monthly and taking into account stock-out periods, safety stock, procurement period, and lead time

– 8 months: 21,600 x 8 = 172,800 additional units

Page 16: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Consumption Method (2)

3. Combine total annual consumption with buffer amounts to get total number of units to be ordered – 259,200 + 172,800 = 432,000 units total

4. Subtract any stock on hand

Page 17: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Example of spreadsheet – Consumption Method

(CT) (Dos) (Ca)

DRUG NAME STRENGTH (BU) BU BURifampicin-Isoniazid 150/75 mg TAB 672 259,200 0 21,600Pyrazinamide 400MG TAB 672 168,000 0 14,000Ethambutol 400MG TAB 672 168,000 0 14,000

BASIC unit

PACK SIZE

(28 tabs/ blister,24 blisters)

TOTAL CONSUMP

TION IN PERIOD

DAYS OUT OF STOCK

AVG MTHLY

CONSUMPTION

See handouts in participant’s notebooks for rest of spreadsheet

Page 18: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Adjusted-Consumption Method

• When neither consumption nor morbidity method is feasible

• This option extrapolates consumption data from another region or health system– population-based (medicine use x 1000

population)

– service-based (medicine use per specific patient or case)

Page 19: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

How to make TB quantification easier?

• Use fixed dose combination medicines with 3 or 4 medicines in one tablet

• Use patient kits where all medicines needed for a full course of treatment are in one product (patient pack)

• Both reduce the number of products to count

For example:Current regimen: (RH)+ Z+ E = 3 products

If use 4 FDC (RHZE) = 1 product If use patient kit = 1 product

Page 20: Quantification from a TB Perspective Technical Briefing Seminar for Consultants on Procurement & Supply Management for HIV, TB and Malaria Jan. 31 2006.

Summary – Quantification

• Needed for:– Planning, budgeting, and ordering

• Critical issues:– Must first have good selection of drugs

– Decide who will quantify – centralized (NTP) vs. decentralized activity

– Tools to use - manual vs. computerized

– Knowledge of lead times, stock-outs, safety stock, growth, losses, existing stocks

– Reconcile quantities needed with budget